vs
Ginkgo Bioworks Holdings, Inc.（DNA）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.7倍（$57.1M vs $33.4M），REGIS CORP同比增速更快（22.3% vs -23.8%），REGIS CORP自由现金流更多（$891.0K vs $-47.7M），过去两年REGIS CORP的营收复合增速更高（7.8% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
DNA vs RGS — 直观对比
营收规模更大
RGS
是对方的1.7倍
$33.4M
营收增速更快
RGS
高出46.1%
-23.8%
自由现金流更多
RGS
多$48.6M
$-47.7M
两年增速更快
RGS
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $57.1M |
| 净利润 | — | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 10.8% |
| 净利率 | — | 0.8% |
| 营收同比 | -23.8% | 22.3% |
| 净利润同比 | — | -94.0% |
| 每股收益（稀释后） | $-1.41 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNARGS
| Q4 25 | $33.4M | $57.1M | ||
| Q3 25 | $38.8M | $59.0M | ||
| Q2 25 | $49.6M | $60.4M | ||
| Q1 25 | $48.3M | $57.0M | ||
| Q4 24 | $43.8M | $46.7M | ||
| Q3 24 | $89.0M | $46.1M | ||
| Q2 24 | $56.2M | $49.4M | ||
| Q1 24 | $37.9M | $49.2M |
净利润DNARGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | $-80.8M | $1.4M | ||
| Q2 25 | $-60.3M | $116.5M | ||
| Q1 25 | $-91.0M | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-56.4M | $-853.0K | ||
| Q2 24 | $-217.2M | $91.2M | ||
| Q1 24 | $-165.9M | $-2.3M |
营业利润率DNARGS
| Q4 25 | -211.9% | 10.8% | ||
| Q3 25 | -231.8% | 10.0% | ||
| Q2 25 | -132.1% | 12.1% | ||
| Q1 25 | -184.1% | 8.8% | ||
| Q4 24 | -236.3% | 11.8% | ||
| Q3 24 | -62.0% | 4.6% | ||
| Q2 24 | -396.7% | — | ||
| Q1 24 | -469.1% | 8.3% |
净利率DNARGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | -207.9% | 2.3% | ||
| Q2 25 | -121.6% | 192.9% | ||
| Q1 25 | -188.2% | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | -63.3% | -1.9% | ||
| Q2 24 | -386.4% | 184.7% | ||
| Q1 24 | -437.3% | -4.7% |
每股收益（稀释后）DNARGS
| Q4 25 | $-1.41 | $0.16 | ||
| Q3 25 | $-1.45 | $0.49 | ||
| Q2 25 | $-1.10 | $43.67 | ||
| Q1 25 | $-1.68 | $0.08 | ||
| Q4 24 | $-1.91 | $2.71 | ||
| Q3 24 | $-1.08 | $-0.36 | ||
| Q2 24 | $-4.23 | $38.40 | ||
| Q1 24 | $-3.32 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $508.6M | $188.7M |
| 总资产 | $1.1B | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资DNARGS
| Q4 25 | $422.6M | $18.4M | ||
| Q3 25 | $495.5M | $16.6M | ||
| Q2 25 | $559.4M | $17.0M | ||
| Q1 25 | $325.3M | $13.3M | ||
| Q4 24 | $561.6M | $10.2M | ||
| Q3 24 | $616.2M | $6.3M | ||
| Q2 24 | $730.4M | $10.1M | ||
| Q1 24 | $840.4M | $5.9M |
总债务DNARGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益DNARGS
| Q4 25 | $508.6M | $188.7M | ||
| Q3 25 | $559.8M | $187.6M | ||
| Q2 25 | $613.0M | $185.6M | ||
| Q1 25 | $647.4M | $68.6M | ||
| Q4 24 | $716.1M | $66.7M | ||
| Q3 24 | $797.9M | $56.4M | ||
| Q2 24 | $833.1M | $56.8M | ||
| Q1 24 | $987.3M | $-35.8M |
总资产DNARGS
| Q4 25 | $1.1B | $588.3M | ||
| Q3 25 | $1.2B | $592.1M | ||
| Q2 25 | $1.2B | $599.0M | ||
| Q1 25 | $1.3B | $511.2M | ||
| Q4 24 | $1.4B | $530.1M | ||
| Q3 24 | $1.5B | $508.9M | ||
| Q2 24 | $1.6B | $530.5M | ||
| Q1 24 | $1.6B | $543.7M |
负债/权益比DNARGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $891.0K |
| 自由现金流率自由现金流/营收 | -142.8% | 1.6% |
| 资本支出强度资本支出/营收 | 0.0% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | — | $14.9M |
8季度趋势，按日历期对齐
经营现金流DNARGS
| Q4 25 | $-47.7M | $1.7M | ||
| Q3 25 | $-31.6M | $2.3M | ||
| Q2 25 | $-40.3M | $6.8M | ||
| Q1 25 | $-51.5M | $6.2M | ||
| Q4 24 | $-42.4M | $2.1M | ||
| Q3 24 | $-103.5M | $-1.3M | ||
| Q2 24 | $-84.4M | $5.1M | ||
| Q1 24 | $-89.3M | $-277.0K |
自由现金流DNARGS
| Q4 25 | $-47.7M | $891.0K | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $-40.3M | $6.2M | ||
| Q1 25 | $-59.1M | $5.9M | ||
| Q4 24 | $-56.1M | $1.7M | ||
| Q3 24 | $-118.6M | $-1.4M | ||
| Q2 24 | $-111.4M | $5.1M | ||
| Q1 24 | $-96.0M | $-326.0K |
自由现金流率DNARGS
| Q4 25 | -142.8% | 1.6% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | -81.2% | 10.3% | ||
| Q1 25 | -122.4% | 10.3% | ||
| Q4 24 | -128.0% | 3.6% | ||
| Q3 24 | -133.2% | -3.0% | ||
| Q2 24 | -198.2% | 10.3% | ||
| Q1 24 | -252.9% | -0.7% |
资本支出强度DNARGS
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.1% | 0.9% | ||
| Q1 25 | 15.8% | 0.6% | ||
| Q4 24 | 31.3% | 0.9% | ||
| Q3 24 | 16.9% | 0.0% | ||
| Q2 24 | 48.1% | 0.0% | ||
| Q1 24 | 17.7% | 0.1% |
现金转化率DNARGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
